vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Metallus Inc. (MTUS). Click either name above to swap in a different company.
Metallus Inc. is the larger business by last-quarter revenue ($267.3M vs $139.2M, roughly 1.9× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -5.3%, a 40.8% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 11.1%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-37.2M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -8.8%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
ADMA vs MTUS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $267.3M |
| Net Profit | $49.4M | $-14.3M |
| Gross Margin | 63.8% | 2.2% |
| Operating Margin | 45.1% | -7.7% |
| Net Margin | 35.5% | -5.3% |
| Revenue YoY | 18.4% | 11.1% |
| Net Profit YoY | -55.9% | 33.2% |
| EPS (diluted) | $0.20 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $267.3M | ||
| Q3 25 | $134.2M | $305.9M | ||
| Q2 25 | $122.0M | $304.6M | ||
| Q1 25 | $114.8M | $280.5M | ||
| Q4 24 | $117.5M | $240.5M | ||
| Q3 24 | $119.8M | $227.2M | ||
| Q2 24 | $107.2M | $294.7M | ||
| Q1 24 | $81.9M | $321.6M |
| Q4 25 | $49.4M | $-14.3M | ||
| Q3 25 | $36.4M | $8.1M | ||
| Q2 25 | $34.2M | $3.7M | ||
| Q1 25 | $26.9M | $1.3M | ||
| Q4 24 | $111.9M | $-21.4M | ||
| Q3 24 | $35.9M | $-5.9M | ||
| Q2 24 | $32.1M | $4.6M | ||
| Q1 24 | $17.8M | $24.0M |
| Q4 25 | 63.8% | 2.2% | ||
| Q3 25 | 56.3% | 11.4% | ||
| Q2 25 | 55.1% | 10.6% | ||
| Q1 25 | 53.2% | 7.8% | ||
| Q4 24 | 53.9% | 4.5% | ||
| Q3 24 | 49.8% | 5.3% | ||
| Q2 24 | 53.6% | 8.2% | ||
| Q1 24 | 47.8% | 15.7% |
| Q4 25 | 45.1% | -7.7% | ||
| Q3 25 | 38.0% | 3.6% | ||
| Q2 25 | 35.1% | 2.8% | ||
| Q1 25 | 30.4% | 1.0% | ||
| Q4 24 | 32.6% | -10.1% | ||
| Q3 24 | 33.1% | -3.1% | ||
| Q2 24 | 36.6% | 2.1% | ||
| Q1 24 | 26.7% | 9.3% |
| Q4 25 | 35.5% | -5.3% | ||
| Q3 25 | 27.1% | 2.6% | ||
| Q2 25 | 28.1% | 1.2% | ||
| Q1 25 | 23.4% | 0.5% | ||
| Q4 24 | 95.2% | -8.9% | ||
| Q3 24 | 30.0% | -2.6% | ||
| Q2 24 | 29.9% | 1.6% | ||
| Q1 24 | 21.7% | 7.5% |
| Q4 25 | $0.20 | $-0.34 | ||
| Q3 25 | $0.15 | $0.19 | ||
| Q2 25 | $0.14 | $0.09 | ||
| Q1 25 | $0.11 | $0.03 | ||
| Q4 24 | $0.45 | $-0.46 | ||
| Q3 24 | $0.15 | $-0.13 | ||
| Q2 24 | $0.13 | $0.10 | ||
| Q1 24 | $0.08 | $0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $156.7M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $686.0M |
| Total Assets | $624.2M | $1.1B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $156.7M | ||
| Q3 25 | $61.4M | $191.5M | ||
| Q2 25 | $90.3M | $190.8M | ||
| Q1 25 | $71.6M | $180.3M | ||
| Q4 24 | $103.1M | $240.7M | ||
| Q3 24 | $86.7M | $254.6M | ||
| Q2 24 | $88.2M | $272.8M | ||
| Q1 24 | $45.3M | $278.1M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $5.4M | ||
| Q4 24 | $72.3M | $5.4M | ||
| Q3 24 | — | $13.2M | ||
| Q2 24 | — | $13.2M | ||
| Q1 24 | — | $13.2M |
| Q4 25 | $477.3M | $686.0M | ||
| Q3 25 | $431.2M | $697.7M | ||
| Q2 25 | $398.3M | $690.0M | ||
| Q1 25 | $373.4M | $686.1M | ||
| Q4 24 | $349.0M | $690.5M | ||
| Q3 24 | $231.9M | $712.7M | ||
| Q2 24 | $188.3M | $736.3M | ||
| Q1 24 | $153.7M | $739.3M |
| Q4 25 | $624.2M | $1.1B | ||
| Q3 25 | $568.7M | $1.2B | ||
| Q2 25 | $558.4M | $1.1B | ||
| Q1 25 | $510.6M | $1.1B | ||
| Q4 24 | $488.7M | $1.1B | ||
| Q3 24 | $390.6M | $1.1B | ||
| Q2 24 | $376.4M | $1.1B | ||
| Q1 24 | $350.9M | $1.2B |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | 0.21× | 0.01× | ||
| Q3 24 | — | 0.02× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $-1.9M |
| Free Cash FlowOCF − Capex | $34.6M | $-37.2M |
| FCF MarginFCF / Revenue | 24.8% | -13.9% |
| Capex IntensityCapex / Revenue | 0.8% | 13.2% |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $-93.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $-1.9M | ||
| Q3 25 | $13.3M | $22.0M | ||
| Q2 25 | $21.1M | $34.8M | ||
| Q1 25 | $-19.7M | $-38.9M | ||
| Q4 24 | $50.2M | $13.9M | ||
| Q3 24 | $25.0M | $-15.3M | ||
| Q2 24 | $45.6M | $8.3M | ||
| Q1 24 | $-2.2M | $33.4M |
| Q4 25 | $34.6M | $-37.2M | ||
| Q3 25 | $-1.1M | $-6.4M | ||
| Q2 25 | $18.7M | $17.0M | ||
| Q1 25 | $-24.4M | $-66.4M | ||
| Q4 24 | $47.5M | $-1.3M | ||
| Q3 24 | $24.0M | $-32.9M | ||
| Q2 24 | $43.6M | $-5.8M | ||
| Q1 24 | $-4.6M | $16.0M |
| Q4 25 | 24.8% | -13.9% | ||
| Q3 25 | -0.8% | -2.1% | ||
| Q2 25 | 15.3% | 5.6% | ||
| Q1 25 | -21.2% | -23.7% | ||
| Q4 24 | 40.4% | -0.5% | ||
| Q3 24 | 20.0% | -14.5% | ||
| Q2 24 | 40.7% | -2.0% | ||
| Q1 24 | -5.6% | 5.0% |
| Q4 25 | 0.8% | 13.2% | ||
| Q3 25 | 10.7% | 9.3% | ||
| Q2 25 | 2.0% | 5.8% | ||
| Q1 25 | 4.1% | 9.8% | ||
| Q4 24 | 2.3% | 6.3% | ||
| Q3 24 | 0.9% | 7.7% | ||
| Q2 24 | 1.9% | 4.8% | ||
| Q1 24 | 2.9% | 5.4% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 2.72× | ||
| Q2 25 | 0.62× | 9.41× | ||
| Q1 25 | -0.73× | -29.92× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | 1.80× | ||
| Q1 24 | -0.12× | 1.39× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
MTUS
| Industrial Market Sector | $95.3M | 36% |
| Manufactured Components | $67.8M | 25% |
| Aerospace And Defense | $39.6M | 15% |
| Seamless Mechanical Tubing | $31.3M | 12% |
| Energy Market Sector | $18.3M | 7% |
| Other | $11.3M | 4% |
| Other Market Sector | $3.7M | 1% |
